[ E-scape Bio raises $63M in Series A ]

E-scape Bio has raised $63 million in Series A funding.

Founded in 2015, E-scape Bio is a biopharmaceutical company focused on the discovery and development of small-molecule drugs to treat genetically-defined subpopulations in neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.

The company’s therapeutic programs are designed to restore normal function disrupted by inherited genetic mutations causing the disease.

Funding  Series A
Founded  2015
Country  USA
City  San Francisco, California
Founder / CEO  /
Deal Size  $63M
Investors  Sutter Hill Ventures
 Osage University Partners
  Novartis Venture Fund
 Johnson & Johnson Innovation
 Novo A/S
Previous Investors  /